ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Ca...
Oric Pharmaceuticals, Inc. (ORIC)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer. The posters can be found in the publication section of ORIC’s website here. “Our research continues to show the therapeutic potential of PRC2 inhibition across the prostate cancer disease spectrum, by reducing tumor adaptability and sustaining the benefit derived from androgen-receptor targeted therapies,” said Lori Friedman, PhD, chief scientific officer. “Additionally, our preclinical studies reveal that targeting PRC2 via EED has potential advantages over targeting EZH2, whi
Show less
Read more
Impact Snapshot
Event Time:
ORIC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORIC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORIC alerts
High impacting Oric Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ORIC
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICPR Newswire
- ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICGlobeNewswire
- ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
- A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data [Yahoo! Finance]Yahoo! Finance
ORIC
Earnings
- 2/23/26 - Beat
ORIC
Sec Filings
- 3/31/26 - Form 8-K
- 2/26/26 - Form 4
- 2/24/26 - Form 144
- ORIC's page on the SEC website